Bazedoxifene Suppresses Intracellular *Mycobacterium tuberculosis* Growth by Enhancing Autophagy

Qi Ouyang,a Kehong Zhang,a,b Dachuan Lin,a Carl G. Feng,a,c Yi Cai,a Xinchun Chena

aGuangdong Provincial Key Laboratory of Regional Immunity and Diseases, Department of Pathogen Biology, School of Medicine, Shenzhen University, Shenzhen, China
bDepartment of Pharmaceutical/Medicinal Chemistry, Institute of Pharmacy, Friedrich-Schiller-University Jena, Jena, Germany
cImmunology and Host Defense Group, Department of Infectious Diseases and Immunology, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia

ABSTRACT Tuberculosis (TB) is still the leading killer caused by *Mycobacterium tuberculosis* infection. There is a clear need for new treatment strategy against TB. It has been reported that tamoxifen, known as a selective estrogen receptor modulator (SERM), exhibits antimycobacterial activity and inhibits *M. tuberculosis* growth in macrophages. However, it remains unknown whether such antimicrobial activity is a general property of all SERMs and how it works. In this study, we identified that bazedoxifene (BZA), a newer SERM, inhibits intracellular *M. tuberculosis* growth in macrophages. BZA treatment increases autophagosome formation and LC3B-II protein expression in *M. tuberculosis*-infected macrophages. We further demonstrated that the enhancement of autophagy by BZA is dependent on increased reactive oxygen species (ROS) production and associated with phosphorylation of Akt/mTOR signaling. In summary, our data reveal a previously unappreciated antimicrobial function of BZA and suggest that future investigation focusing on the mechanism of action of SERMs in macrophages may lead to new host-directed therapies against TB.

IMPORTANCE Since current strategies for the treatment of multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) have low efficacy and highly negative side effects, research on new treatments including novel drugs is essential for curing drug-resistant tuberculosis. Host-directed therapy (HDT) has become a promising idea to modulate host cell responses to enhance protective immunity against pathogens. Bazedoxifene (BZA), which belongs to a new generation of SERMs, shows the ability to inhibit the growth of *M. tuberculosis* in macrophages and is associated with autophagy. Our findings reveal a previously unrecognized antibacterial function of BZA. We propose that the mechanism of SERMs action in macrophages may provide a new potential measure for host-directed therapies against TB.

KEYWORDS *Mycobacterium tuberculosis*, autophagy, bazedoxifene, host-directed therapy

Tuberculosis (TB), a chronic infectious disease caused by *Mycobacterium tuberculosis*, remains as a leading killer worldwide. In 2018, there were more than 10 million new cases and 1.57 million deaths from TB occurred (1). Although current antibiotics are effective at treating the majority of active TB cases, there is still a relapse rate of up to 9% even after completion of a 6- to 9-month treatment regimen (2, 3). Moreover, the emergence of drug-resistant TB (4), as in the case of multiple-drug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) (5), has further impeded the effectiveness of the current regimen. This situation has led to the emergence of a new paradigm in TB drug discovery that involves therapeutic modulation of host cell functions in order to improve pathogen eradication, namely, host-directed therapy (HDT) (6). Since the

Citation Ouyang Q, Zhang K, Lin D, Feng CG, Cai Y, Chen X. 2020. Bazedoxifene suppresses intracellular *Mycobacterium tuberculosis* growth by enhancing autophagy. mSphere 5:e00124-20. https://doi.org/10.1128/mSphere.00124-20.

Editor Christina L. Stallings, Washington University School of Medicine in St. Louis

Copyright © 2020 Ouyang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.

Address correspondence to Yi Cai, caiyi0113@szu.edu.cn, or Xinchun Chen, chenxinchun@szu.edu.cn.

Received 6 February 2020
Accepted 19 March 2020
Published 8 April 2020
mechanisms underlying HDT are completely different from those for antibiotics, which directly kill the mycobacteria, HDT has become an attractive strategy to shorten treatment regimens and to treat TB patients infected with drug-resistant *M. tuberculosis* strains (6, 7).

Tamoxifen (TAM), known as a selective estrogen receptor modulator (SERM), is widely used for the treatment of breast cancer (8). It has been initially suggested to have antimycobacterial activity using the computationally predicted “TB drugome” approach—a method for drug repositioning for tuberculosis treatment (9). In line with this, a recent study revealed that TAM exhibits antimycobacterial activity against drug-resistant *M. tuberculosis* and inhibits intracellular *M. tuberculosis* growth in macrophages (10). However, the underlying mechanism remains largely unknown. In particular, it is uncertain whether inhibition of intracellular *M. tuberculosis* growth by TAM is due to direct killing of bacteria or to modulation of bactericidal activity of macrophages. In addition, it remains to be elucidated whether other SERMs exhibit similar antimycobacterial effects in human macrophages.

In this study, we investigated whether bazedoxifene (BZA), a newer SERM that is effective in TAM-resistant breast cancer and has a high safety profile (11), has an antimycobacterial effect. We found that BZA efficiently inhibits intracellular *M. tuberculosis* growth in human macrophages.

As well, the autophagic machinery is a fundamental cellular response to defense against infectious pathogens, including *M. tuberculosis* infections (12). During autophagy, *M. tuberculosis* is sequestered within a double-membrane cytosolic vesicle called the autophagosome (13). After that, autophagosomes mature into autolysosomes through fusion with lysosomes, which leads to the digestion and death of the microbes (14) and subsequently activates the innate and adaptive immunity (15–17). In this study, we also identified that BZA inhibition is associated with enhanced autophagy.

RESULTS

**BZA inhibits intracellular *M. tuberculosis* growth in macrophages.** To investigate whether BZA has a direct antimycobacterial activity similar to TAM, we treated *Mycobacterium smegmatis* and *M. tuberculosis* H37Ra with BZA at different concentrations directly. Our data showed that BZA did not inhibit the growth of *M. smegmatis* and *M. tuberculosis* H37Ra at concentrations up to 20 μM (10.613 μg/ml) (Fig. 1A). Although the growth rate of *M. tuberculosis* H37Ra was statistically different from the control group when the concentration was up to 20 μM, the bacterial growth inhibition efficiency was very low, less than 20% (Fig. 1B). While exhibiting a moderate inhibitory effect on *M. smegmatis* and *M. tuberculosis* H37Ra growth at a concentration higher than 200 μM, BZA at this concentration caused significant cytotoxicity with 52% cell viability (see Fig. S1 in the supplemental material).

We next investigated whether BZA could inhibit *M. tuberculosis* growth indirectly through enhancing macrophage bactericidal activity. We observed that when used at a dose (5 μM) that did not display apparent inhibitory effect on *M. tuberculosis* growth in 7H9 medium, BZA significantly inhibited both *M. tuberculosis* H37Ra and H37Rv growth in THP-1 macrophages as determined by counting CFU at 72 h postinfection (Fig. 1C and D). These results indicated that BZA significantly suppresses intracellular *M. tuberculosis* growth through modulating macrophage functions.

**BZA inhibits intracellular *M. tuberculosis* growth in macrophages through enhancing autophagy.** We next investigated the mechanism underlying BZA inhibition of intracellular *M. tuberculosis* growth. Since autophagy is critical for macrophages to inhibit *M. tuberculosis* growth (18, 19) and previous studies have demonstrated that BZA induces autophagy in cancer cells (20), we first investigated the effect of BZA on autophagy induction. As expected, we found that BZA treatment significantly increased autophagy in macrophages, regardless of *M. tuberculosis* infection, as evident from a significantly increased conversion of soluble LC3B-I to lipid bound LC3B-II (Fig. 2A and Fig. S2A). To further examine the effect of BZA on autophagy flux, we monitored LC3B...
aggregation in autophagosomes and autolysosomes using the stably transformed monomeric red fluorescent protein (mRFP)-green fluorescent protein (GFP)-LC3 re-porter THP-1 cells. Our result shows that BZA treatment significantly increased autophagosome and autolysosome forming punctate in H37Ra-infected cells compared with their mock-treated counterparts. (Fig. 2B to D), suggesting that enhanced autophagy contributes to BZA-mediated suppression of intracellular \textit{M. tuberculosis} growth.

To determine the causal relationship between the effect of BZA on intracellular \textit{M. tuberculosis} growth and its role in inducing autophagy, bafilomycin A1 (Baf), an autophagy inhibitor that prevents maturation of autophagic vacuoles by inhibiting fusion between autophagosomes and lysosomes (21), was used to block autophagy induced by BZA. As expected, the cumulative amount of LC3B-II increased after using Baf in H37Ra- or H37Rv-infected macrophages treated with BZA (Fig. S2B and C), indicating that the increased accumulation of LC3B-II promoted by BZA is not due to the inhibition of downstream autophagic flow. Another autophagy inhibitor, 3-methyladenine (3-MA), a phosphatidylinositol 3-kinase (PI3K) inhibitor (22), was also used to block autophagy in the presence of BZA, and intracellular \textit{M. tuberculosis} load was determined by CFU counting. As expected, 3-MA significantly reduced BZA-induced autophagy as determined by immunoblotting of LC3B-II conversion (Fig. 3A) as
well as by counting and analyzing autophagosome and autolysosome formation in mRFP-GFP-LC3B reporter cells (Fig. 3B to D). Importantly, the inclusion of 3-MA almost completely abrogated BZA-mediated suppression of *M. tuberculosis* growth within macrophages (Fig. 3E), indicating the effect of BZA on intracellular *M. tuberculosis* growth was dependent on its role in regulating autophagy.

To confirm the role of autophagy in BZA-mediated suppression of intracellular *M. tuberculosis* growth, we knocked down ATG5, a key protein in autophagy initiation and processing (23), and analyzed the effect of BZA on macrophage bactericidal activity. As demonstrated in Fig. 3F, ATG5 expression was significantly reduced following the treatment with ATG5-specific small interfering RNA (siRNA) for 36 h (Fig. 3F). In agreement with 3-MA treatment experiments, we found that ATG5 knockdown almost completely abolished BZA-mediated inhibition of intracellular growth of *M. tuberculosis* (Fig. 3G). However, we did not observe a significant increase of CFU in the siATG5 group compared to the control (Fig. 3G), which might be due to the knockdown efficiency, as a previous study showed that the complete knockout of ATG5 showed only a slight increase in CFU compared to wild-type (WT) macrophages (24). Taken together, these data confirmed that BZA suppresses *M. tuberculosis* growth in macrophages through enhancing autophagosome formation.
Inhibiting autophagy-mediated impairment of BZA induced bacterial activity against *M. tuberculosis* in macrophages. (A) PMA-differentiated THP-1 macrophages were infected with H37Ra (MOI = 10:1) for 24 h in the presence or absence of BZA (5 μM) and 3-MA (10 mM). The LC3B-II protein level was analyzed by Western blotting. (B) mRFP-GFP-LC3B reporter THP-1 cells were differentiated by PMA and infected with H37Ra (MOI = 10:1) with or without BZA (5 μM) and 3-MA (10 mM) for 12 h. Representative confocal microscopy images are shown (bars, 5 μm). (C and D) The autophagosome puncta (yellow) per cell (C) and the autolysosome puncta (red) per cell (D) were calculated. (E) PMA-differentiated THP-1 macrophages were infected with H37Ra (MOI = 10:1) for 6 h. After washing three times with prewarmed sterile phosphate-buffered saline (PBS) to remove extracellular bacteria, the infected THP-1 cells were treated with or without BZA (5 μM) and 3-MA (10 mM) for another 72 h. Cells were lysed in 0.1% SDS and plated on 7H10 plates. The bactericidal activity of macrophages was assessed by determining CFU of intracellular H37Ra. (F) PMA-differentiated THP-1 macrophages were transfected with ATG5 small interfering RNA (siRNA) for 36 h. Scrambled siRNA was used as a negative control. These macrophages were then infected with H37Ra (MOI = 10:1) and treated with BZA (5 μM) as described above. The ATG5 protein level was analyzed by Western blotting. ATG5/β-actin ratios are shown above the protein band. (G) The bactericidal activity of macrophages treated as described above was assessed by CFU. The data represent the means ± standard deviations (SD) for three independent experiments. Values that are significantly different by one-way ANOVA are indicated by asterisks as follows: *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001 (ns, not significant).
BZA-induced autophagy is associated with ROS production and phosphorylation of Akt/mTOR signal. To determine the mechanisms by which the BZA modulates macrophage bactericidal capability against *M. tuberculosis*, we also investigated the effect of BZA on *M. tuberculosis*-induced reactive oxygen species (ROS) production, one of the pivotal mechanisms for the killing of intracellular *M. tuberculosis* by macrophages (25). We found that mitochondrial ROS (mROS) production (Fig. 4A) was significantly increased in *M. tuberculosis*-infected macrophages upon treatment with BZA at 24 h postinfection, whereas cytoplasmic ROS (cROS) was not significantly changed (Fig. 4B).

It has been reported that mitochondrial ROS is an important mediator of autophagy (26, 27). We therefore used N-acetyl-L-cysteine (NAC), a ROS-scavenging agent, in the presence of BZA treatment to test whether increased mROS contributes to enhanced autophagy induced by BZA in *M. tuberculosis*-infected macrophages. In line with previous reports (28, 29), we found that addition of NAC abolished the ability of BZA to induce autophagy (Fig. 4C).

Phosphorylation of mTOR and Akt is a key signaling step for the initiation of autophagy (30, 31). To gain an insight into the signaling for BZA-induced autophagy, we determined the phosphorylation of mTOR, Akt, ULK, AMPK, and STAT3. There was
no difference in the extent of ULK, AMPK, and STAT3 phosphorylation between the presence and absence of BZA treatment (Fig. 5A). In contrast, the levels of phospho-mTOR and phospho-Akt in BZA-treated M. tuberculosis-infected macrophages were significantly reduced (Fig. 5B) in comparison with those without BZA treatment. These results imply that BZA-induced autophagy is associated with phosphorylation of mTOR and Akt signaling.

**DISCUSSION**

With the emergence of drug-resistant TB, there is an urgent need for new TB treatment strategies. Repurposed FDA-approved drugs for anti-TB therapy are an attractive approach due to the safety profile of the approved products. In this study, we show that BZA, a newer SERM, significantly inhibits M. tuberculosis growth in human macrophages. This effect of BZA is mediated through enhancing autophagy in infected macrophages. We propose that BZA treatment increases mROS production and promotes autophagosome formation in macrophages, which ultimately enhances the passage of M. tuberculosis into the phagolysosome for pathogen destruction.

BZA is an indole-based estrogen receptor (ER) ligand with a unique structure, which differs from TAM and raloxifene (32) but exhibits similar functions (33). BZA is well tolerated and possesses improved inhibitory potency against the Y537S and D538G ERa mutants compared to TAM (34). In contrast to previous reports that TAM has direct antimycobacterial activity at a low concentration (16 μM) (10), we found that BZA displays only moderate antimycobacterial activity in 7H9 culture medium at a high concentration (200 μM). Therefore, these findings suggest that TAM and BZA limit mycobacterial growth through both shared and distinct mechanisms. The exact reason underlying the difference between TAM and BZA in extracellular bacterial killing is currently unknown, although this could be due simply to the intrinsic differences in their chemical structure. However, consistent with TAM and raloxifene (10, 35, 36), we found that BZA significantly enhanced the macrophage bactericidal activity against M. tuberculosis. More importantly, we confirmed that this effect of BZA is achieved through regulating autophagy activity in macrophages. By simultaneously analyzing the amount of LC3B-II and the formation of the autophagosome and autolysosome, we inferred that BZA facilitates autophagic activity and therefore enhances the elimination of intracellular M. tuberculosis via autophagosome synthesis and lysosome degradation.

How autophagy is regulated in M. tuberculosis-infected macrophages is complex. It has been reported that ROS can induce autophagy (37), one means of which is through the inhibition of Akt signaling, and mTOR (38). In line with this report, we found that mROS production was elevated after BZA treatment in M. tuberculosis-infected macrophages and that depletion of mROS by NAC abolished BZA-induced autophagy. However, our data have not addressed the exact signal pathway from ROS to autophagy during BZA treatment. Although we demonstrated that the disruption of

---

**FIG 5** BZA reduced Akt/mTOR levels in macrophages. THP-1 macrophages were differentiated by PMA and infected with H37Ra (MOI = 10:1) for 24 h in the presence or absence of BZA (5 μM) and NAC (5 mM). The phospho-ULK, phospho-AMPK, and phospho-STAT3 protein levels (A) and phospho-mTOR and phospho-Akt protein levels (B) from H37Ra-infected THP-1 macrophages with or without BZA (5 μM) and NAC (5 mM) treatment were analyzed by Western blotting.

---

March/April 2020 Volume 5 Issue 2 e00124-20

msphere.asm.org
autophagy abolished the effect of BZA and that BZA-induced autophagy was dependent on the upregulation of mROS production, we cannot exclude and discriminate the contribution of direct killing bacteria by mROS.

In summary, we have demonstrated that BZA significantly inhibits intracellular *M. tuberculosis* growth in macrophages through enhancing ROS production and autophagy. These findings suggest that BZA may be considered a host-directed drug candidate for TB treatment and that further in *vivo* investigations are warranted.

**MATERIALS AND METHODS**

**Bacterial strains and culture conditions.** *M. smegmatis* mc^155^ and *M. tuberculosis* strains H37Ra and H37Rv were used. The bacteria were grown in Middlebrook 7H9 broth (BBL Microbiology Systems) supplemented with 10% oleic acid-albumin-dextrose-catalase (OADC; Becton, Dickinson), 0.05% Tween 80 (Sigma), and 0.2% glycerol (Sigma); for 5 to 7 days at 37°C with shaking to achieve mid-logarithmic phase (optical density at 600 nm (OD_{600}) = 0.3 to 0.8). The bacteria were resuspended in serum-free RPMI medium and sonicated to obtain a single-cell suspension before being used in experiments. The concentration of bacteria was determined by the OD_{600} as a function of CFU per milliliter.

**Cell culture and chemicals.** Cells of the human monocytic cell line THP-1 were purchased from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). THP-1 cells and THP-1 cells transformed with an mRFP-GFP-LC3B reporter (provided by Hongbo Shen, Institute Pasteur of Shanghai, China) were maintained in RPMI 1640 (Corning) culture medium supplemented with 10% fetal bovine serum (FBS; Invitrogen, Life Technologies) at 37°C and 5% CO2. The THP-1 cells were seeded at 5 × 10^6 cells/ml in a 12-well plate in complete RPMI 1640 and differentiated using phorbol 12-myristate 13-acetate (PMA; Sigma, P8139) at 40 ng/ml for 24 h. Following removal of the PMA-containing medium, the cells were incubated in the fresh complete RPMI 1640 medium for 12 h at 37°C for further use.

Bazedoxifene (acetate) (BZA) was purchased from MedChemExpress (MCE; China), and a 10 mM stock solution was dissolved and diluted in dimethyl sulfoxide (DMSO; Sigma, USA). Bafilomycin A1 (Baf), 5-acetyl-L-cysteine (NAC), and 3-methyladenine (3-MA) were purchased from Sigma-Aldrich (Sigma, USA). The final concentration of DMSO in treatment did not exceed 0.1% (vol/vol).

**Extracellular H37Ra survival determination.** *In vitro* antimycobacterial activity was tested with *M. smegmatis* and *M. tuberculosis* H37Ra. The bacteria were diluted with 7H9-OADC to an OD of 0.01 and transferred to a 96-well microtiter plate for the survival assay. Then, BZA with a serial dilution of 10-fold in 7H9 medium was added to the bacterial culture. DMSO was added as a negative control. The bacterial plates were incubated at 37°C with horizontal shaking (110 rpm). The absorbance of OD_{600} was measured with an Epoch 2 microplate spectrophotometer (BioTek, USA) at indicated times, and the growth rate of bacteria was calculated.

**Cell viability and proliferation assay.** THP-1 cells (5 × 10^4 cells/well) were incubated in a 96-well plate with 40 ng/ml PMA for 24 h. Cells were then maintained in fresh prewarmed complete RPMI 1640 for 12 h at 37°C for further use. Different concentration of BZA (200 μM, 20 μM, and 2 μM) and DMSO, as a negative control, were added and cultured for an additional 72 h. WST-1 reagent (Beyotime, Shanghai, China) was added into the well (10 μl/well) and incubated at 37°C for 2 h to measure cell viability and proliferation. The absorbance was measured at 450 nm and 690 nm with an Epoch 2 microplate spectrophotometer (BioTek, USA), and cell viability was calculated according to the manufacturer’s instructions.

**CFU assays.** PMA-differentiated THP-1 macrophages (5 × 10^6 cells) were infected with two laboratory *M. tuberculosis* strains (H37Ra and H37Rv) at a multiplicity of infection (MOI) of 10 for 6 h at 37°C, 5% CO2. After washing three times with prewarmed sterile phosphate-buffered saline (PBS) to remove extracellular bacteria, the infected THP-1 cells are treated with or without BZA (5 μM) for another 72 h. Cells were washed three times with PBS and then lysed with 500 μl of PBS containing 0.1% SDS. Triple experimental groups for each treatment were plated on Middlebrook 7H10 agar (Difco; Middlebrook) supplemented with 10% OADC and incubated vertically at 37°C for 3 weeks, and then the colonies were counted. CFU obtained from two or three dilutions was used to calculate the total number of CFU per milliliter. Data were presented as the amount of *M. tuberculosis* in 5 × 10^6 cells and the percentage of mycobacterial survival in BZA-treated and untreated cells.

**Measurement of H37Ra in lysosomes and colocalization with LC3B.** mRFP-GFP-LC3B reporter THP-1 macrophages (1 × 10^6 cells/ml) were differentiated using PMA and infected with mycobacterial strain H37Ra (MOI of 10:1) for 6 h. After washing with PBS, the cells were cultured with or without BZA (5 μM) for 12 h. The cells were then washed twice in PBS and with 4% paraformaldehyde solution (Solarbio, China) for 15 min at room temperature. Cells were stained with Hoechst stain and mounted with antifade agent (Invitrogen, USA). The cells were visualized, and images were acquired with an Olympus FV1000 confocal microscope (Nikon A1R) and processed using Image J software (NIH, USA).

**Measurement of ROS.** PMA-differentiated THP-1 macrophages (5 × 10^6 cells/ml) were cultured in 12-well plates and infected with H37Ra (MOI of 10:1) for 6 h. Extracellular bacteria were removed by washing 3 times with prewarmed sterile PBS. The cells were cultured in fresh medium with or without BZA (5 μM) for 24 h. The generation of cytoplasmic ROS (cROS) was quantified using 5- (and -6)-chloromethyl-2',7'-dichlorodihydrofluorescein diacetate, acetyl ester (CM-H2DCF-DA) (Invitrogen, USA), according to the manufacturer’s instructions. The generation of mitochondrial ROS (mROS) was quan-
tified using MitoSOX red mitochondrial superoxide indicator (Invitrogen, USA). The cells were incubated with H2O2/DA (10 μM) and MitoSOX (10 μM) for 15 min at 37°C in the dark. All fluorescence intensities of cells were measured by flow cytometry (BD FACSAria II flow cytometer) and analyzed by FlowJo 6.1 according to the manufacturer’s protocol.

**RNA interference and transfection.** PMA-differentiated THP-1 macrophages (5 × 10⁴ cells/ml) were transfected with ATGS siRNA (RiboBio; siB12531154855-1-5; China) using Lipofectamine RNAiMAX (ThermoFisher, USA) according to the manufacturer’s protocol. The siRNA and Lipofectamine complexes were prepared in Opti-MEM (Gibco) at a 1:1 ratio. Negative control (NC) vector without any insert was used as a negative control. The medium was replaced after 36 h, cells were washed twice with PBS before lysing, and the efficiency of knockdown was determined by Western blotting. For the CFU test, THP-1 cells were infected with H37Rv (MOI of 10:1) for 6 h after 36 h of treatment with siRNA silencing. Extracellular bacteria were washed 3 times with prewarmed serum-free RPMI and treated with BZA for 72 h.

**Western blot analysis.** PMA-differentiated THP-1 macrophages (5 × 10⁴ cells/ml) were cultured in 12-well plates and infected with H37Rv (MOI of 10:1) with or without BZA (5 μM) for 6, 12, or 24 h. After washing with PBS, the cells were lysed in RIPA lysis buffer (Cell Signaling Technology). The protein concentration of the resultant lysates was measured with a bicinchoninic acid (BCA) protein kit (Beyo-

**ACKNOWLEDGMENTS**

We thank Stefan Oehlers and all participants and site staff of Sydney University (Sydney, Australia), for their contributions to the study. We also thank Hongbo Shen (Institute Pasteur of Shanghai, China) for gifting mRFP-GFP-LC3B THP-1 cells and for assistance in detecting autophagic flux.

This study was supported by the Natural Science Foundation of China (81770013, 81525016, 81871255, and 91942315), the National Science and Technology Major Project (2017ZX100210301), the Science and Technology Project of Shenzhen (JCYJ20170412101048337), and the Guangdong Provincial Science and Technology Program (2019B030301009). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**REFERENCES**

1. World Health Organization. 2019. Global tuberculosis report 2018. World Health Organization, Geneva, Switzerland.

2. Thomas A, Gopi P, Santha T, Chandrasekaran V, Subramani R, Selvakumaran N, Eusuff S, Sadakarath K, Narayanan P. 2005. Predictors of relapse among pulmonary tuberculosis patients treated in a DOTS programme in South India. Int J Tuberc Lung Dis 9:556–561.

3. Azhar GS. 2012. DOTS for TB relapse in India: a systematic review. Lung India 29:147–153. https://doi.org/10.4103/0970-2113.93320.

4. Palomino JC, Martin A. 2014. Drug resistance mechanisms in Mycobacterium tuberculosis. Antibiotics 3:317–340. https://doi.org/10.3390/antibiotics3030317.

5. Pinto L, Menzies D. 2011. Treatment of drug-resistant tuberculosis. Infect Drug Resist 4:129–135. https://doi.org/10.2147/IDR.S10332.

6. Kaufmann SH, Dohi K, Hotchkiss RS, Bartenschlager R. 2018. Host-directed therapies for bacterial and viral infections. Nat Rev Drug Discov 17:35–56. https://doi.org/10.1038/nrd.2017.162.

7. Brown RE, Hunter RL, Hwang S-A. 2017. Morphoproteomic-guided host-directed therapy for tuberculosis. Front Immunol 8:78. https://doi.org/10.3389/fimmu.2017.00078.

8. An K-C. 2016. Selective estrogen receptor modulators. Asian Spine J 10:787–791. https://doi.org/10.4184/asj.2016.10.4.787.

9. Chen F-C, Liao Y-C, Huang J-M, Lin C-H, Chen Y-Y, Dou H-Y, Hsiung CA. 2014. Pros and cons of the tuberculosis drugome approach—an empirical analysis. PLoS One 9:e100829. https://doi.org/10.1371/journal.pone.0100829.

10. Jang WS, Kim S, Podder B, Jyoti MA, Nam K-W, Lee B-E, Song H-Y. 2015.
20. Leignadier J, Dalenc F, Poirot M, Silvente-Poirot S. 2017. Improving the
23. Okerlund ND, Schneider K, Leal-Ortiz S, Montenegro-Venegas C, Kim SA,
15. Levine B, Kroemer G. 2008. Autophagy in the pathogenesis of disease.
12. De Chastellier C. 2009. The many niches and strategies used by patho-
18. Fabri M, Realegeno SE, Jo E-K, Modlin RL. 2011. Role of autophagy in the
14. Rogov V, Dötsch V, Johansen T, Kirkin V. 2014. Interactions between
19. Lam A, Prabhu R, Gross CM, Riesenberg LA, Singh V, Aggarwal S. 2017. Role
13. Mizushima N, Levine B, Cuervo AM, Klionsky DJ. 2008. Autophagy fights

22. Bento CF, Empadinhas N, Mendes V. 2015. Autophagy in the fight
tuberculosis. DNA Cell Biol 34:228–242. 2015:E8711–E8720.

26. Scherz-Shouval R, Elazar Z. 2007. ROS, mitochondria and the regulation of
autophagy. Trends Cell Biol 17:422–427. https://doi.org/10.1016/j.tcb .2007.07.009.

27. Filomeni G, De Zio D, Cecconi F. 2015. Oxidative stress and autophagy:
the clash between damage and metabolic needs. Cell Death Differ 22:377–388.
https://doi.org/10.1038/cdd.2014.150.

28. Sun Y-S. 2010. N-acetylcysteine, reactive oxygen species and beyond.
Cancer Biol Ther 9:109–110. https://doi.org/10.4161/cbt.9.2.10583.

29. Shimamoto K, Hayashi H, Tanial E, Morita R, Imaoka M, Ishii Y, Suzuki K,
Shibutani M, Mitsuokari K. 2011. Antioxidant N-acetyl-L-cysteine (NAC)
supplementation reduces reactive oxygen species (ROS)-mediated hep-
atocellular tumor promotion of indole-3-carbinol (I3C) in rats. J Toxicol
Sci 36:775–786. https://doi.org/10.2131/jts.36.775.

30. Feng H, Cheng X, Kung J, Chen L, Yuen S, Shi M, Liang J, Shen B, Jin Z,
Yan J, Qiu W. 2018. Apatinib-induced protective autophagy and apo-
ptosis through the AKT–mTOR pathway in anaplastic thyroid cancer. Cell
Death Dis 9:1030. https://doi.org/10.1038/s41419-018-1054-3.

31. Xue J-F, Shi Z-M, Zou J, Li X-L. 2017. Inhibition of PI3K/AKT/mTOR
signaling pathway promotes autophagy of articular chondrocytes and
attenuates inflammatory response in rats with osteoarthritis. Biomed
Pharmacother 89:1252–1261. https://doi.org/10.1016/j.biopharm.2017.01 .130.

32. Wardell SE, Nelson ER, Chao CA, McDonnell DP. 2013. Bazexodifene exhibits
antiestrogenic activity in animal models of tamoxifen-resistant breast
cancer: implications for treatment of advanced disease. Clin Cancer Res
19:2420–2431. https://doi.org/10.1158/1078-0432.CCR-12-3771.

33. Komm BS, Kharode YP, Bodine PV, Harris HA, Miller CP, Lyttle CR. 2005.
Bazexodifene acetate: a selective estrogen receptor modulator with improved selectivity. Endocrinology 146:3999–4008. https://doi.
org/10.1210/en.2005-0030.

34. Fanning SW, Jeselsohn R, Dharmarajan V, Mayne CG, Karimi M, Buch-
walter G, Houtman R, Toy W, Fowler CE, Han R, Laine M, Carlson KE,
Martin TA, Nowak J, Nwachukwu JC, Hosfield DJ, Chandrarlapaty S,
Tajkhorshid E, Nettles KW, Griffin PR, Shen Y, Katzenellenbogen JA,
Brown M, Greene GL. 2018. The SERM/SERD bazexodifene disrupts ESR1
helic 12 to overcome acquired hormone resistance in breast cancer cells.
Elife 7:e37161. https://doi.org/10.7554/elife.37161.

35. Feng X, Zhu W, Schurig-Briccio LA, Lindert S, Shoen C, Hitchings R, Ri J, Jiang
Y, Wang Y, Baig N, Zhou T. 2015. Antiinfective targeting enzymes and the
proton motive force. Proc Natl Acad Sci U S A 112:E7073–E7082. https://doi.
org/10.1073/pnas.1521988112.

36. Lupien A, Vocat A, Foo C-Y, Blattes E, Gillon J-Y, Makarov V, Cole ST. 2018.
Optimized background regimen for treatment of active tuberculosis with
the next-generation benzothiazinone macozaine (PTBZ169), Anti-
timicrob Agents Chemother 62:e00840-18. https://doi.org/10.1128/AAC .00840-18.

37. Shin D-M, Jeon B-Y, Lee H-M, Jin HS, Z-W, Cho S-N, Kim J-M. 2010. Mycobacterium
tuberculosis eis regulates intramacrophage Mycobacterium tuberculosis. J Microbiol
Biotechnol 20:22:377–388. https://doi.org/10.4175/jmbs.2010.3.

38. Bolisetty S, Jaimes E. 2013. Mitochondria and reactive oxygen species:
physiology and pathophysiology. Int J Mol Sci 14:6306–6344. https://doi.
org/10.3390/ijms14036306.